技术领域technical field
本发明属于医药技术领域，具体涉及一种含AKT抑制剂和IRE1抑制剂的药物组合物及其应用。The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition containing an AKT inhibitor and an IRE1 inhibitor and application thereof.
背景技术Background technique
癌症是仅次于心血管疾病的高死亡率疾病，全球癌症患者和死亡病例都在不断地增加。新增癌症病例有近一半出现在亚洲，其中大部分在中国，中国新增癌症病例高居世界第一位。尤其是在肝癌、食管癌、胃癌和肺癌等4种恶性肿瘤中，中国新增病例和死亡人数均居世界首位。这些癌症的治疗虽然以手术为主，但由于早期患者一般无明显症状，在首次被确诊的癌症患者中，很多已为中晚期，失去了手术切除的机会，故非手术治疗在肿瘤的综合治疗中有着十分重要的地位。其中，化疗无论是术前化疗、术后辅助化疗还是姑息性化疗，在综合治疗中占据举足轻重的地位。目前常用的化疗药物多以长春瑞滨、紫杉醇、氟尿嘧啶、顺铂、5-氟尿嘧啶为主，其产生的化疗反应，如恶心呕吐较强烈以及对肝肾功能和骨髓损害等，一定程度上限制了其应用。Cancer is a disease with a high mortality rate second only to cardiovascular diseases, and the number of cancer patients and deaths worldwide is increasing. Nearly half of the new cancer cases occurred in Asia, most of which were in China, which ranked first in the world in terms of new cancer cases. Especially in the four types of malignant tumors including liver cancer, esophageal cancer, gastric cancer and lung cancer, China ranks first in the number of new cases and deaths in the world. Although the treatment of these cancers is mainly based on surgery, since early patients generally have no obvious symptoms, many of the cancer patients diagnosed for the first time are already in the middle and advanced stages and have lost the chance of surgical resection. has a very important position. Among them, whether it is preoperative chemotherapy, postoperative adjuvant chemotherapy or palliative chemotherapy, chemotherapy occupies a pivotal position in the comprehensive treatment. Currently commonly used chemotherapeutic drugs are mainly vinorelbine, paclitaxel, fluorouracil, cisplatin, and 5-fluorouracil. The chemotherapeutic reactions produced by them, such as strong nausea and vomiting, and damage to liver and kidney function and bone marrow, limit the its application.
AKT信号传导通路是细胞内重要的信号传导通路之一，它参与调节肿瘤细胞的增殖、存活、迁移、黏附、肿瘤血管生成等过程，并在多种常见肿瘤(如乳腺癌、肺癌、胃癌、前列腺癌、宫颈癌和血液系统肿瘤)中均有高表达。因此，以AKT为靶点的分子靶向治疗也逐渐得到人们的重视。其中，MK-2206是一种高度选择性的AKT1/2/3抑制剂，其主要作用是抑制AKT磷酸化，对250种其他蛋白激酶没有抑制活性，目前已进入Ⅱ期临床试验研究。Perifosine(KRX-0401)是一种新型的AKT抑制剂，为一杂环的烷基磷酸胆碱，可靶向作用于Akt的pleckstrin同源结构域来抑制AKT的活性，表现出良好的抑制乳腺癌在内的多种实体瘤活性，目前已进入Ⅲ期临床试验研究。Ipatasertib(GDC-0068)是一种高选择性的广谱AKT抑制剂，靶向作用于AKT1/2/3，比作用于PKA选择性高620倍，目前已进入Ⅱ期临床试验研究。AZD5363作为AKT抑制剂，可有效抑制AKT(AKT1/2/3)的所有亚型，对P70S6K/PKA也具有相似的抑制效果，而对ROCK1/2抑制活性较低，目前已进入Ⅱ期临床试验研究。The AKT signal transduction pathway is one of the important signal transduction pathways in cells. It participates in the regulation of tumor cell proliferation, survival, migration, adhesion, tumor angiogenesis and other processes, and is involved in many common tumors (such as breast cancer, lung cancer, gastric cancer, Highly expressed in prostate cancer, cervical cancer and blood system tumors). Therefore, molecular targeted therapy targeting AKT has gradually gained people's attention. Among them, MK-2206 is a highly selective AKT1/2/3 inhibitor, its main function is to inhibit the phosphorylation of AKT, and has no inhibitory activity on 250 other protein kinases. It has entered phase II clinical trial research. Perifosine (KRX-0401) is a new type of AKT inhibitor, which is a heterocyclic alkyl phosphorylcholine, which can target the pleckstrin homology domain of Akt to inhibit the activity of AKT, showing good inhibition of mammary gland The activity of a variety of solid tumors including cancer has entered phase III clinical trials. Ipatasertib (GDC-0068) is a highly selective broad-spectrum AKT inhibitor, targeting AKT1/2/3, which is 620 times more selective than PKA, and has entered phase II clinical trials. As an AKT inhibitor, AZD5363 can effectively inhibit all subtypes of AKT (AKT1/2/3), and has a similar inhibitory effect on P70S6K/PKA, but has low inhibitory activity on ROCK1/2, and has entered phase II clinical trials Research.
肌醇需求激酶1(IRE1)是一种定位于内质网膜的跨膜蛋白，参于未折叠蛋白反应(UPR)信号通路中信息的传递。其中，IRE1α/Xbp1通路是UPR的重要传感通路，IRE1α通过感知内质网压力，使激酶区域自磷酸化进而激活核酸酶活性，在mRNA水平上剪切其下游转录因子Xbp1，激活一系列的UPR相关基因的转录，从而缓解内质网压力，还可通过非依赖Xbp1的途径，激活JNK，引发细胞的凋亡。STF-083010是一种特异性IRE1核酸内切酶抑制剂，具有剂量和时间依赖性的细胞抑制能力和细胞毒性，STF-083010可抑制XBP1剪接，抑制IRE1α的核酸内切酶活性，但不影响IRE1α的激酶活性。APY29是IRE1变构调节剂，能抑制IRE1R自磷酸化，并激活IRE1RNase活性。而4μ8C是高效的选择性IRE1抑制剂，它可阻断基底(RIDD)接近IRE1的活性部位，并选择性使Xbp1剪接作用和IRE1介导的mRNA降解失活。目前，关于IRE1α/Xbp1通路的研究多与脂肪代谢调控有关，很少涉及到肿瘤的防治。Inositol-requiring kinase 1 (IRE1) is a transmembrane protein localized in the endoplasmic reticulum membrane, which is involved in the transmission of information in the unfolded protein response (UPR) signaling pathway. Among them, the IRE1α/Xbp1 pathway is an important sensing pathway of UPR. IRE1α senses endoplasmic reticulum pressure, autophosphorylates the kinase region and activates nuclease activity, cleaves its downstream transcription factor Xbp1 at the mRNA level, and activates a series of Transcription of UPR-related genes can relieve endoplasmic reticulum pressure, and activate JNK through an Xbp1-independent pathway to trigger cell apoptosis. STF-083010 is a specific IRE1 endonuclease inhibitor with dose- and time-dependent cytostatic ability and cytotoxicity, STF-083010 can inhibit XBP1 splicing, inhibit IRE1α endonuclease activity, but does not affect Kinase activity of IRE1α. APY29 is an allosteric modulator of IRE1, which can inhibit IRE1R autophosphorylation and activate IRE1 RNase activity. 4μ8C is a potent and selective IRE1 inhibitor, which can block basal (RIDD) access to the active site of IRE1 and selectively inactivate Xbp1 splicing and IRE1-mediated mRNA degradation. At present, most of the research on the IRE1α/Xbp1 pathway is related to the regulation of fat metabolism, and seldom involves the prevention and treatment of tumors.
随着肿瘤分子生物学的研究进展，肿瘤分子靶向治疗已成为肿瘤研究的热点，在多种肿瘤的治疗中发挥了重要的作用。然而，大部分肿瘤的生物学行为并非由单一信号传导通路所支配，而是多个信号传导通路共同起作用的，因此联合用药针对多靶点进行靶向治疗将不仅旨在减少或延缓耐药性的出现、降低毒性，而且通过多种药物对癌细胞杀伤的协同作用取得更好的疗效。目前，没有关于AKT抑制剂和IRE1抑制剂联合用药用于抗肿瘤的相关研究报道。With the progress of tumor molecular biology research, tumor molecular targeted therapy has become a hot spot in tumor research and plays an important role in the treatment of various tumors. However, the biological behavior of most tumors is not dominated by a single signal transduction pathway, but multiple signal transduction pathways work together, so combined drug therapy targeting multiple targets will not only aim to reduce or delay drug resistance The emergence of sex, reduce toxicity, and achieve better curative effect through the synergistic effect of multiple drugs on cancer cell killing. At present, there is no relevant research report on the combined use of AKT inhibitors and IRE1 inhibitors for anti-tumor.
发明内容Contents of the invention
为解决现有技术存在的问题，本发明的目的在于提供一种药物组合物及其在制备防治肿瘤的药物中的应用，具体涉及含有AKT抑制剂和IRE1抑制剂的药物组合物及其在制备治疗肺癌、肝癌、食管癌、肠癌、胃癌、脑瘤、胰腺癌、卵巢癌、乳腺癌或前列腺癌的药物中的应用。In order to solve the problems in the prior art, the object of the present invention is to provide a pharmaceutical composition and its application in the preparation of drugs for the prevention and treatment of tumors, in particular to a pharmaceutical composition containing an AKT inhibitor and an IRE1 inhibitor and its preparation Use in medicines for the treatment of lung cancer, liver cancer, esophageal cancer, bowel cancer, stomach cancer, brain tumor, pancreatic cancer, ovarian cancer, breast cancer or prostate cancer.
本发明提供一种药物组合物，其包含有AKT抑制剂和IRE1抑制剂。The invention provides a pharmaceutical composition comprising an AKT inhibitor and an IRE1 inhibitor.
其中，所述的AKT抑制剂选自MK-2206、Perifosine(KRX-0401)、Ipatasertib(GDC-0068)或AZD5363。Wherein, the AKT inhibitor is selected from MK-2206, Perifosine (KRX-0401), Ipatasertib (GDC-0068) or AZD5363.
所述的IRE1抑制剂选自STF-083010、APY29或4μ8C。The IRE1 inhibitor is selected from STF-083010, APY29 or 4μ8C.
优选地，所述的AKT抑制剂为MK-2206。Preferably, the AKT inhibitor is MK-2206.
优选地，所述的IRE1抑制剂为STF-083010。Preferably, the IRE1 inhibitor is STF-083010.
优选地，所述的药物组合物包含有MK-2206和STF-083010。Preferably, the pharmaceutical composition contains MK-2206 and STF-083010.
进一步地，所述的药物组合物中MK-2206和STF-083010的摩尔浓度比为1～20:10～60。Further, the molar concentration ratio of MK-2206 and STF-083010 in the pharmaceutical composition is 1-20:10-60.
优选地，所述的药物组合物中MK-2206和STF-083010的摩尔浓度比为5:40。Preferably, the molar concentration ratio of MK-2206 and STF-083010 in the pharmaceutical composition is 5:40.
此外，本发明还请求保护上述的药物组合物在制备防治肿瘤药物中的应用，所述的肿瘤包括但不限于肺癌、肝癌、食管癌、肠癌、胃癌、脑瘤、胰腺癌、卵巢癌、乳腺癌或前列腺癌。In addition, the present invention also claims the application of the above-mentioned pharmaceutical composition in the preparation of drugs for the prevention and treatment of tumors, including but not limited to lung cancer, liver cancer, esophageal cancer, intestinal cancer, gastric cancer, brain tumor, pancreatic cancer, ovarian cancer, breast or prostate cancer.
优选地，本发明请求保护上述的药物组合物在制备防治肺癌、肝癌、食管癌药物中的应用。Preferably, the present invention claims the application of the above-mentioned pharmaceutical composition in the preparation of drugs for preventing and treating lung cancer, liver cancer and esophageal cancer.
进一步地，所述的药物组合物可配以药学可接受的添加剂制成注射制剂或口服制剂，优选注射制剂，尤其是静脉注射制剂。Furthermore, the pharmaceutical composition can be formulated with pharmaceutically acceptable additives to make injection or oral preparations, preferably injection preparations, especially intravenous injection preparations.
磷脂酰肌醇-3-激酶(PI3K)及蛋白激酶B(AKT)所组成的信号通路与肿瘤增殖、凋亡、转移、侵袭及血管生成密切相关。作为该通路的核心，异常活化的AKT通过磷酸化其下游分子(如mTOR)促进肿瘤恶性增殖及抵抗凋亡，并参与调节肿瘤对放化疗及靶向治疗的敏感性。特异性抑制AKT分子活化能有效阻断PI3K/AKT信号通路，抑制肿瘤增殖，促进凋亡。本发明人以MK-2206单独处理食管癌细胞株Kyse450、Kyse510、TE-1、Eca-109、EC9706，发现MK-2206对食管癌细胞的生长具有一定的抑制作用，使癌症细胞数明显减少，并且发现MK-2206通过抑制AKT及mTOR的磷酸化，使p-AKT和p-mTOR的表达显著下调，从而有效阻断PI3K/AKT/mTOR信号通路，充分发挥抑制肿瘤增殖，促进凋亡效果。The signaling pathway composed of phosphatidylinositol-3-kinase (PI3K) and protein kinase B (AKT) is closely related to tumor proliferation, apoptosis, metastasis, invasion and angiogenesis. As the core of this pathway, abnormally activated AKT promotes tumor malignant proliferation and resists apoptosis by phosphorylating its downstream molecules (such as mTOR), and participates in regulating tumor sensitivity to radiotherapy, chemotherapy and targeted therapy. Specifically inhibiting the activation of AKT molecules can effectively block the PI3K/AKT signaling pathway, inhibit tumor proliferation, and promote apoptosis. The inventors treated esophageal cancer cell lines Kyse450, Kyse510, TE-1, Eca-109, and EC9706 with MK-2206 alone, and found that MK-2206 had a certain inhibitory effect on the growth of esophageal cancer cells, significantly reducing the number of cancer cells. It was also found that MK-2206 significantly down-regulated the expression of p-AKT and p-mTOR by inhibiting the phosphorylation of AKT and mTOR, thereby effectively blocking the PI3K/AKT/mTOR signaling pathway, fully exerting the effect of inhibiting tumor proliferation and promoting apoptosis.
一方面，本发明人以MK-2206和STF-083010联合用药，观察其对食管癌、肺癌、肝癌细胞和正常血管内皮细胞的影响，结果发现，MK-2206和STF-083010联合用药，可显著抑制癌细胞的存活，减少癌细胞的数量，效果显著优于单独使用MK-2206或STF-083010，对食管癌、肺癌、肝癌细胞的抑制效果均显示出较佳的协同作用，同时，联合用药对正常血管内皮细胞的毒性较小。On the one hand, the inventors used MK-2206 and STF-083010 in combination to observe its effects on esophageal cancer, lung cancer, liver cancer cells and normal vascular endothelial cells, and found that the combination of MK-2206 and STF-083010 can significantly Inhibiting the survival of cancer cells and reducing the number of cancer cells, the effect is significantly better than that of MK-2206 or STF-083010 alone, and the inhibitory effects on esophageal cancer, lung cancer, and liver cancer cells all show better synergy. At the same time, the combined drug It is less toxic to normal vascular endothelial cells.
另一方面，本发明人还考察了MK-2206和STF-083010联合用药对食管癌细胞克隆形成的影响，结果显示，与对照组以及单药组相比，联合用药对细胞克隆形成具有明显的协同抑制作用，联合用药组细胞克隆数量最少，同时体积也最小，表明MK-2206和STF-083010联合用药联合用药对抑制食管癌细胞克隆具有较佳的协同作用。On the other hand, the inventors also investigated the effect of the combination of MK-2206 and STF-083010 on the colony formation of esophageal cancer cells. Synergistic inhibitory effect, the number of cell clones in the combined drug group was the least, and the volume was also the smallest, indicating that the combined drug of MK-2206 and STF-083010 has a better synergistic effect on inhibiting esophageal cancer cell clones.
与现有技术相比，本发明的优势在于：Compared with the prior art, the present invention has the advantages of:
本发明提供一种用于防治肿瘤的药物组合物，具体为将AKT抑制剂和IRE1抑制剂组合使用，更具体为以MK-2206和STF-083010联合用药，为肿瘤患者提供一种新的治疗方案，所述的MK-2206和STF-083010联合用药，可有效抑制肿瘤细胞的生长和细胞克隆形成，效果显著优于单独用药，具有相加或协同效应，同时对正常细胞的毒副作用低，安全性高，可应用于制备抗肿瘤的药物领域。The present invention provides a pharmaceutical composition for preventing and treating tumors, specifically combining AKT inhibitors and IRE1 inhibitors, more specifically combining MK-2206 and STF-083010 to provide a new treatment for tumor patients According to the scheme, the combination of MK-2206 and STF-083010 can effectively inhibit the growth of tumor cells and the formation of cell clones, and the effect is significantly better than that of single drugs, with additive or synergistic effects, and at the same time, it has low toxic and side effects on normal cells. The method has high safety and can be applied to the field of preparing antitumor drugs.
附图说明Description of drawings
图1MK-2206单独使用对食管癌细胞生长的影响。Figure 1 Effect of MK-2206 alone on the growth of esophageal cancer cells.
图2MK-2206单独使用对食管癌细胞形态的影响。Figure 2 The effect of MK-2206 alone on the morphology of esophageal cancer cells.
图3MK-2206单独使用对食管癌细胞mTOR/AKT通路的影响。Figure 3 The effect of MK-2206 alone on the mTOR/AKT pathway in esophageal cancer cells.
图4MK-2206与STF-083010联合作用对食管癌细胞生长的影响。Fig. 4 Effect of combined action of MK-2206 and STF-083010 on the growth of esophageal cancer cells.
图5MK-2206与STF-083010联合作用对食管癌细胞形态的影响。Fig. 5 Effect of combined action of MK-2206 and STF-083010 on morphology of esophageal cancer cells.
图6MK-2206与STF-083010联合作用对食管癌细胞的联用效果分析。Figure 6 Analysis of the combined effect of MK-2206 and STF-083010 on esophageal cancer cells.
图7MK-2206、顺铂、5-氟尿嘧啶与STF-083010联合作用对肿瘤细胞及正常细胞的影响。Fig. 7 Effect of combined action of MK-2206, cisplatin, 5-fluorouracil and STF-083010 on tumor cells and normal cells.
图8MK-2206与STF-083010联合作用对食管癌细胞克隆形成的影响。Fig. 8 Effect of combined action of MK-2206 and STF-083010 on colony formation of esophageal cancer cells.
具体实施方式Detailed ways
以下通过具体实施方式进一步描述本发明，但本发明不仅仅限于以下实施例。The present invention is further described below through specific embodiments, but the present invention is not limited only to the following examples.
实施例1MK-2206单独处理后对食管癌细胞生长的影响Effect of embodiment 1MK-2206 on the growth of esophageal cancer cells after being treated alone
首先检测Kyse450、Kyse510、TE-1、Eca-109、EC9706食管癌细胞对MK-2206单独使用的药物敏感性。First, detect the drug sensitivity of Kyse450, Kyse510, TE-1, Eca-109, EC9706 esophageal cancer cells to MK-2206 alone.
1、实验方法1. Experimental method
将肿瘤细胞以每孔4000-6000个细胞的数量接种到96孔板，待细胞贴壁(24h)后，将MK-2206药物稀释成一定的梯度浓度，每浓度设5复孔，分为实验组及调零组加药。48h后采用MTT法进行细胞活力检测，每孔加入10μl MTT溶液，继续培养4h，小心吸除孔内液体，避免接触孔内结晶物，每孔加入100μl的DMSO，于恒速摇床上避光摇晃。待结晶物充分溶解后，在酶标仪上读取OD值(波长570nm，参考波长630nm)，测得吸光度A值。The tumor cells were inoculated into 96-well plates at the number of 4000-6000 cells per well. After the cells adhered to the wall (24 hours), the MK-2206 drug was diluted to a certain gradient concentration, and each concentration was set to 5 replicate wells, divided into experimental Group and zero group dosing. After 48 hours, use the MTT method to detect cell viability. Add 10 μl of MTT solution to each well and continue to incubate for 4 hours. Carefully suck out the liquid in the wells to avoid contact with crystals in the wells. Add 100 μl of DMSO to each well and shake on a constant speed shaker in the dark. . After the crystals are fully dissolved, read the OD value (wavelength 570nm, reference wavelength 630nm) on a microplate reader, and measure the absorbance A value.
生长抑制率的计算公式为：生长抑制率(％)＝(1-OD实验组/OD对照组)×100％。根据各浓度的抑制率可作图得到剂量反应曲线，作图软件为Graphpad，采用Logit法精确计算药物的IC50(half maximal inhibitory concentration)值。具体结果见图1和图2。The calculation formula of growth inhibition rate is: growth inhibition rate (%)=(1-OD experimental group/OD control group)×100%. According to the inhibition rate of each concentration, the dose-response curve can be obtained by plotting. The plotting software is Graphpad, and the IC50 (half maximal inhibitory concentration) value of the drug is accurately calculated by the Logit method. The specific results are shown in Figure 1 and Figure 2.
从图1可以看出，MK-2206对食管癌细胞株Kyse450、Kyse510、TE-1、Eca-109、EC9706的IC50值分别为14.3、12.4、9.4、7.6和11.5，表明MK-2206对食管癌细胞的生长具有一定的抑制作用。从图2也可以看出，MK-2206单独作用于食管癌细胞株Kyse450、Kyse510后，细胞数明显减少。It can be seen from Figure 1 that the IC50 values of MK-2206 against esophageal cancer cell lines Kyse450, Kyse510, TE-1, Eca-109, and EC9706 were 14.3, 12.4, 9.4, 7.6, and 11.5, respectively, indicating that MK-2206 has an effect on esophageal cancer cells. The growth of cancer cells has a certain inhibitory effect. It can also be seen from Figure 2 that after MK-2206 alone acts on esophageal cancer cell lines Kyse450 and Kyse510, the number of cells is significantly reduced.
实施例2MK-2206单独使用对食管癌细胞mTOR/AKT通路的影响Example 2 Effect of MK-2206 alone on mTOR/AKT pathway in esophageal cancer cells
利用Western blot方法检测经MK-2206单独处理及联合处理后食管癌细胞Kyse450和Kyse510细胞内mTOR/AKT通路相关蛋白的表达情况。先将Kyse450和Kyse510细胞分别以每孔2×105个细胞的密度接种至6孔板。待细胞贴壁后，按实施例1给药。处理48h后，分别收取各组细胞全蛋白。先经SDS电泳后，将蛋白转移至PVDF膜上，5％脱脂奶粉室温封闭1h，孵育所需检测的蛋白相对应的一抗，4℃孵育过夜。24h回收一抗，用TBST清洗3次，每次5min，之后孵育二抗，室温孵育1h。后用TBST清洗3次，每次5min，之后ECL显影，结果见图3。Western blot method was used to detect the expression of mTOR/AKT pathway-related proteins in esophageal cancer cells Kyse450 and Kyse510 cells treated with MK-2206 alone or in combination. First, Kyse450 and Kyse510 cells were seeded into 6-well plates at a density of2 ×105 cells per well. After the cells adhered to the wall, the drug was administered according to Example 1. After 48 hours of treatment, the whole protein of cells in each group was collected separately. After SDS electrophoresis, the protein was transferred to a PVDF membrane, blocked with 5% skimmed milk powder at room temperature for 1 hour, incubated with the primary antibody corresponding to the protein to be detected, and incubated overnight at 4°C. After 24 hours, the primary antibody was recovered, washed three times with TBST for 5 minutes each time, and then incubated with the secondary antibody for 1 hour at room temperature. Afterwards, wash with TBST for 3 times, each time for 5 minutes, and then develop with ECL. The results are shown in Figure 3.
从图3可以看出，在Kyse450和Kyse510细胞中，当用MK-2206单独处理后，p-AKT和p-mTOR的表达显著下调，说明MK-2206能够抑制AKT及mTOR的磷酸化，使p-AKT和p-mTOR的表达显著下调，从而有效阻断PI3K/AKT/mTOR信号通路，充分发挥抑制肿瘤增殖，促进凋亡效果。It can be seen from Figure 3 that in Kyse450 and Kyse510 cells, when treated with MK-2206 alone, the expression of p-AKT and p-mTOR was significantly down-regulated, indicating that MK-2206 can inhibit the phosphorylation of AKT and mTOR, and make p The expression of -AKT and p-mTOR was significantly down-regulated, thereby effectively blocking the PI3K/AKT/mTOR signaling pathway, fully exerting the effect of inhibiting tumor proliferation and promoting apoptosis.
实施例3MK-2206与STF-083010联合作用对食管癌细胞生长的影响Example 3 Effect of MK-2206 combined with STF-083010 on the growth of esophageal cancer cells
将人食管癌细胞Kyse450和Kyse510细胞以每孔4000-6000个细胞的数量接种到96孔板，待细胞贴壁后，加入5μM浓度MK-2206和40μM浓度STF-083010，培养48h后，每孔加入10μl浓度为5mg/ml的MTT溶液，继续培养4h，然后弃去培养液每孔加入100μl的DMSO，于恒速摇床上避光摇晃。待结晶物充分溶解后，在酶标仪上读取OD值(波长570nm，参考波长630nm)，读取每孔的吸光值，计算两药合用后细胞存活率。用CompuSyn软件进行协同作用综合因子(Combination Index,CI)分析，结果见图4。并通过显微镜观察5μM浓度MK-2206和40μM浓度STF-083010联合作用于食管癌细胞细胞形态变化，结果如图5。Human esophageal cancer cells Kyse450 and Kyse510 cells were inoculated into 96-well plates at the number of 4000-6000 cells per well. After the cells adhered to the wall, 5 μM concentration of MK-2206 and 40 μM concentration of STF-083010 were added. After 48 hours of culture, each well was Add 10 μl of MTT solution with a concentration of 5 mg/ml, continue to incubate for 4 h, then discard the culture solution, add 100 μl of DMSO to each well, and shake on a constant speed shaker in the dark. After the crystals are fully dissolved, read the OD value (wavelength 570nm, reference wavelength 630nm) on a microplate reader, read the absorbance value of each well, and calculate the cell survival rate after the combination of the two drugs. CompuSyn software was used to analyze the synergy comprehensive factor (Combination Index, CI), and the results are shown in Figure 4. The morphological changes of esophageal cancer cells were observed under the microscope when MK-2206 at a concentration of 5 μM and STF-083010 at a concentration of 40 μM were combined, as shown in Figure 5 .
如图4所示，5μM浓度MK-2206和40μM浓度STF-083010联合使用具有很好的联用效果。从图5可知，MK-2206与STF-083010两药联用后癌细胞数明显减少，细胞形态较正常组及单独用药组相比无明显变化。As shown in Figure 4, the combined use of 5 μM concentration of MK-2206 and 40 μM concentration of STF-083010 has a good combination effect. It can be seen from Figure 5 that the number of cancer cells was significantly reduced after the combination of MK-2206 and STF-083010, and the cell morphology had no significant change compared with the normal group and the single drug group.
CI值表示药物联合作用时的一个复合指数，CI值小于1、等于和大于1分别表示药物协同作用、增效作用和拮抗作用。从图6可以看出，MK-2206和STF-083010对食管癌细胞联合使用时，其CI值基本都在小于1的范围内，特别是Kyse450，表明MK-2206和STF-083010在本发明的用量范围内联合使用具有很好的协同作用。The CI value represents a composite index when drugs are combined, and CI values less than 1, equal to, and greater than 1 represent synergistic, synergistic, and antagonistic effects of drugs, respectively. It can be seen from Figure 6 that when MK-2206 and STF-083010 are used in combination against esophageal cancer cells, the CI values are basically in the range of less than 1, especially for Kyse450, which shows that MK-2206 and STF-083010 are in the range of the present invention. Combined use within the dosage range has a good synergistic effect.
实施例4MK-2206、顺铂、5-氟尿嘧啶和STF-083010联合作用对肿瘤细胞及正常细胞的影响Example 4 Effects of MK-2206, cisplatin, 5-fluorouracil and STF-083010 in combination on tumor cells and normal cells
将Kyse450食管癌、Kyse510食管癌、A549肺癌、HepG2肝癌细胞和HUVEC正常血管内皮细胞以每孔3000-6000个细胞的数量接种到96孔板，待细胞贴壁后，加入对照组、5μM的MK-2206和40μM的STF-083010及联合用药组药物；另铺细胞Kyse450，按照如下方式进行加药：对照组、5μM MK-2206、40μM STF-083010、MK-2206+STF-083010、1μg/ml顺铂(CDDP)、顺铂(CDDP)+STF-083010、4μg/ml 5-氟尿嘧啶(5-FU)、5-氟尿嘧啶(5-FU)+STF-083010，培养48h后，每孔加入10μl浓度为5mg/ml的MTT溶液，继续培养4h，然后弃去培养液每孔加入100μl的DMSO，于恒速摇床上避光摇晃。待结晶物充分溶解后，在酶标仪上读取OD值(波长570nm，参考波长630nm)，读取每孔的吸光值，计算两药合用后的细胞存活及抑制率，结果见图7。Inoculate Kyse450 esophageal cancer, Kyse510 esophageal cancer, A549 lung cancer, HepG2 liver cancer cells and HUVEC normal vascular endothelial cells into 96-well plates at the number of 3000-6000 cells per well. After the cells adhere to the wall, add the control group and 5 μM MK -2206 and 40μM STF-083010 and drugs in the combined drug group; another cell Kyse450 was added, and the drug was added as follows: control group, 5μM MK-2206, 40μM STF-083010, MK-2206+STF-083010, 1μg/ml Cisplatin (CDDP), cisplatin (CDDP)+STF-083010, 4 μg/ml 5-fluorouracil (5-FU), 5-fluorouracil (5-FU)+STF-083010, after culturing for 48 hours, add 10 μl concentration to each well MTT solution of 5 mg/ml was used to continue culturing for 4 hours, then the culture solution was discarded and 100 μl of DMSO was added to each well, and shaken on a constant speed shaker in the dark. After the crystals are fully dissolved, read the OD value (wavelength 570nm, reference wavelength 630nm) on a microplate reader, read the absorbance value of each well, and calculate the cell survival and inhibition rate after the two drugs are combined. The results are shown in Figure 7.
如图7所示，YM155和STF-083010在肿瘤细胞中组合使用具有很好的联合效果，且优于顺铂、5-氟尿嘧啶与STF-083010组合，而对正常HUVEC细胞的毒性较小。As shown in Figure 7, the combined use of YM155 and STF-083010 in tumor cells has a good combined effect, which is superior to the combination of cisplatin, 5-fluorouracil and STF-083010, and has less toxicity to normal HUVEC cells.
实施例5MK-2206和STF-083010联合用药对食管癌细胞克隆形成的影响Example 5 Effects of MK-2206 and STF-083010 Combined Drugs on the Colony Formation of Esophageal Cancer Cells
将人食管癌细胞Kyse450和Kyse510细胞接种到6孔板，待细胞贴壁过夜后，将细胞分为对照组、MK-2206单药组、STF-083010单药组及MK-2206和STF-083010药物联合用药组，分别加入对应的培养基或者药物溶液，孵育7天，检测细胞平板克隆形成情况。结果如图8所示，与对照组以及单药组相比，联合用药对细胞克隆形成具有明显的协同抑制作用，联合用药组细胞克隆数量最少，同时体积也最小。Human esophageal cancer cells Kyse450 and Kyse510 cells were inoculated into 6-well plates. After the cells adhered overnight, the cells were divided into control group, MK-2206 single-drug group, STF-083010 single-drug group and MK-2206 and STF-083010 In the drug combination group, the corresponding culture medium or drug solution was added, incubated for 7 days, and the formation of cell plate clones was detected. The results are shown in Figure 8. Compared with the control group and the single drug group, the combined drug has an obvious synergistic inhibitory effect on the formation of cell clones, and the combined drug group has the least number of cell clones and the smallest volume.
以上仅是本发明的优选实施方式，应当指出的是，上述优选实施方式不应视为对本发明的限制，本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说，在不脱离本发明的精神和范围内，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。The above are only preferred implementations of the present invention, and it should be noted that the above preferred implementations should not be regarded as limiting the present invention, and the scope of protection of the present invention should be based on the scope defined in the claims. For those skilled in the art, without departing from the spirit and scope of the present invention, some improvements and modifications can also be made, and these improvements and modifications should also be regarded as the protection scope of the present invention.
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710135038.3ACN106822904B (en) | 2017-03-08 | 2017-03-08 | Pharmaceutical composition containing AKT inhibitor and IRE1 inhibitor and application thereof |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710135038.3ACN106822904B (en) | 2017-03-08 | 2017-03-08 | Pharmaceutical composition containing AKT inhibitor and IRE1 inhibitor and application thereof |
| Publication Number | Publication Date |
|---|---|
| CN106822904A CN106822904A (en) | 2017-06-13 |
| CN106822904Btrue CN106822904B (en) | 2019-10-25 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710135038.3AActiveCN106822904B (en) | 2017-03-08 | 2017-03-08 | Pharmaceutical composition containing AKT inhibitor and IRE1 inhibitor and application thereof |
| Country | Link |
|---|---|
| CN (1) | CN106822904B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020019107A1 (en)* | 2018-07-23 | 2020-01-30 | Fosun Orinove Pharmatech, Inc. | IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT |
| JP7468829B2 (en)* | 2018-07-23 | 2024-04-16 | フォースン オリノーヴ ファーマテック インコーポレイテッド | IRE1α INHIBITORS IN COMBINATION WITH CANCER THERAPEUTICS FOR TREATING CANCER - Patent application |
| AU2018447495A1 (en)* | 2018-11-02 | 2021-06-17 | Fosun Orinove Pharmatech, Inc. | IRE1α inhibitor in combination with cancer therapeutic agent for cancer treatment |
| CN116549442A (en)* | 2023-06-08 | 2023-08-08 | 复旦大学 | Application of STF-083010 in the preparation of drugs for the prevention and treatment of aortic dissection |
| CN119656157B (en)* | 2025-01-13 | 2025-06-10 | 安徽农业大学 | Application of 4μ8C in the preparation of preparations for controlling Bombyx mori nuclear polyhedrosis virus |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1934072A (en)* | 2004-01-30 | 2007-03-21 | 派普林生物脂股份有限公司 | Therapeutic and carrier molecules |
| CN102015606A (en)* | 2007-06-08 | 2011-04-13 | 满康德股份有限公司 | IRE-1α inhibitor |
| WO2014176348A1 (en)* | 2013-04-23 | 2014-10-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of the ire-1/xbp-1 pathway and methods of using thereof |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1934072A (en)* | 2004-01-30 | 2007-03-21 | 派普林生物脂股份有限公司 | Therapeutic and carrier molecules |
| CN102015606A (en)* | 2007-06-08 | 2011-04-13 | 满康德股份有限公司 | IRE-1α inhibitor |
| WO2014176348A1 (en)* | 2013-04-23 | 2014-10-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of the ire-1/xbp-1 pathway and methods of using thereof |
| Publication number | Publication date |
|---|---|
| CN106822904A (en) | 2017-06-13 |
| Publication | Publication Date | Title |
|---|---|---|
| CN106822904B (en) | Pharmaceutical composition containing AKT inhibitor and IRE1 inhibitor and application thereof | |
| Riahi-Chebbi et al. | The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells | |
| Hu et al. | Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/β-catenin/c-Myc signaling pathway in human gastric cancer cell | |
| Mohassab et al. | STAT3 transcription factor as target for anti-cancer therapy | |
| TWI663969B (en) | The new cancer therapy indication of the monobenzone | |
| Lu et al. | Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer | |
| CN106963769A (en) | The pharmaceutical composition and its application of inhibitor containing PI3K and PERK inhibitor | |
| CN106822905A (en) | The medicine and purposes of inhibitor containing Survivin and IRE1 inhibitor | |
| Feng et al. | Luteolin, an aryl hydrocarbon receptor ligand, suppresses tumor metastasis in vitro and in vivo | |
| Lin et al. | A polysaccharide from Hedyotis diffusa interrupts metastatic potential of lung adenocarcinoma A549 cells by inhibiting EMT via EGFR/Akt/ERK signaling pathways | |
| CN102526022A (en) | Application of epigallocatechin-3-gallate in preparation of antitumor drug | |
| Guo et al. | (-)-β-hydrastine suppresses the proliferation and invasion of human lung adenocarcinoma cells by inhibiting PAK4 kinase activity | |
| Wang et al. | Identification of WT1 as determinant of heptatocellular carcinoma and its inhibition by Chinese herbal medicine Salvia chinensis Benth and its active ingredient protocatechualdehyde | |
| Li et al. | Proapoptotic and Growth-inhibitory Effects of Plumbagin on Human Gastric Cancer Cells Via Suppression of Signal Transducer and Activator of Transcription 3 and Protein Kinase B. | |
| Lu et al. | Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3‑kinase/protein kinase B/glycogen synthase kinase 3β signaling pathway | |
| Xu et al. | Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis | |
| CN106974908B (en) | Pharmaceutical composition and use containing HDAC inhibitor and IRE1 inhibitor | |
| TWI797426B (en) | Use of chiauranib in treating small cell lung cancer | |
| CN111228272B (en) | Drug mixture and its application in the preparation of drugs for reversing sorafenib resistance in liver cancer | |
| Chi et al. | The natural compound ugonin V targets MMP7 production and restricts chondrosarcoma metastasis by suppressing the MEK/ERK/c-Jun signaling pathways | |
| CN113786491B (en) | An anti-tumor combined preparation containing tetrandrine, dihydroquercetin or quercetin | |
| CN112263578B (en) | Application of Tipranavir in preparation of cancer treatment medicine for killing tumor stem cells and tumor cells | |
| CN103417533A (en) | Application of TPCA-1 as STAT3 signal inhibitor in preparation of antitumor drug | |
| CN112057450A (en) | Nuclear export protein inhibitor KPT-335 and application of composition thereof in antitumor drugs | |
| Kim et al. | Coptis japonica Makino extract suppresses angiogenesis through regulation of cell cycle-related proteins |
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |